The expanding role of pertuzumab in the treatment of HER2-positive breast cancer

The expanding role of pertuzumab in the treatment of HER2-positive breast cancer

I Moya-Horno,1 J Cortés1,2 1Department of Medical Oncology, Instituto Oncológico Baselga, Hospital Quirón, 2Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Barcelona, Spain Abstract: Breast cancer tumors that demonstrate gene amplificatio...

Full description

Bibliographic Details
Main Authors:	Moya-Horno I, Cortés J
Format:	Article
Language:	English
Published:	Dove Medical Press 2015-05-01
Series:	Breast Cancer : Targets and Therapy
Online Access:	http://www.dovepress.com/the-expanding-role-of-pertuzumab-in-the-treatment-of-her2-positive-bre-peer-reviewed-article-BCTT

Similar Items

Role of pertuzumab in the treatment of HER2-positive breast cancer
by: Hubalek M, et al.
Published: (2012-05-01)

Pharmacoeconomic analysis of pertuzumab in treatment of HER2-positive breast cancer in Ukraine
by: О. В. Мужичук, et al.
Published: (2021-03-01)

Cardiotoxicity of Pertuzumab Containing Regimens for HER-2 Positive Breast Cancer
by: Lin, Michelle, et al.
Published: (2017)

EXPERIENCE OF USING PERTUZUMAB IN ANTICANCER THERAPY FOR HER2-POSITIVE BREAST CANCER
by: O. I. Kit, et al.
Published: (2021-05-01)

Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab
by: Jie Li, et al.
Published: (2020-09-01)

Patient with metastatic breast cancer, HER2-positive, trastuzumab- and pertuzumab-resistant responding to lapatinib
by: Daniela Cianniello, et al.
Published: (2018-06-01)

Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
by: Babak Nami, et al.
Published: (2018-09-01)

Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
by: Jagosky M, et al.
Published: (2021-06-01)

Pertuzumab in Combination with Trastuzumab and Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Safety, Efficacy, and Progression Free Survival
by: Joseph J. Maly, et al.
Published: (2014-05-01)

Pertuzumab in Combination with Trastuzumab and Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Safety, Efficacy, and Progression Free Survival
by: Joseph J. Maly, et al.
Published: (2014-01-01)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
by: Jamunarani Veeraraghavan, et al.
Published: (2021-05-01)

Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis
by: Shanshan Chen, et al.
Published: (2019-10-01)

The addition of neoadjuvant pertuzumab for the treatment of HER2+ breast cancer: a cost estimate with real-world data
by: Andreia Borges, et al.
Published: (2021-09-01)

Short term real world safety data of pertuzumab use in HER2 targeted treatment of metastatic breast cancer
by: Ece Esin, et al.
Published: (2018-04-01)

Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel
by: Ashley M. Hopkins, et al.
Published: (2019-08-01)

Safety Assessment of Neoadjuvant Pertuzumab Combined with Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia
by: Nadia Hussain, et al.
Published: (2018-01-01)

Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex.
by: Yue Hao, et al.
Published: (2019-01-01)

Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab
by: Elisabeth Sophie Bergen, et al.
Published: (2021-04-01)

Correction: Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex.
by: Yue Hao, et al.
Published: (2019-01-01)

Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
by: Laura L. Michel, et al.
Published: (2020-10-01)

The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation
by: Babak Nami, et al.
Published: (2019-03-01)

Safety and efficacy of the addition of pertuzumab to T-DM1 ± taxane in patients with HER2-positive, locally advanced or metastatic breast cancer: a pooled analysis
by: Zhang J, et al.
Published: (2017-11-01)

Pertuzumab: Unprecedented benefit in human epidermal growth factor receptor 2-positive breast cancer
by: Amit Rauthan, et al.
Published: (2015-07-01)

Peptide probes derived from pertuzumab by molecular dynamics modeling for HER2 positive tumor imaging.
by: Xiaoliang Yang, et al.
Published: (2017-04-01)

[<sup>89</sup>Zr]-Pertuzumab PET Imaging Reveals Paclitaxel Treatment Efficacy Is Positively Correlated with HER2 Expression in Human Breast Cancer Xenograft Mouse Models
by: Yun Lu, et al.
Published: (2021-03-01)

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.
by: Denis Collins, et al.
Published: (2017-01-01)

Identification of an Activating Mutation in the Extracellular Domain of HER2 Conferring Resistance to Pertuzumab
by: Zhang Y, et al.
Published: (2019-12-01)

Durable Clinical Benefit of Pertuzumab in a Young Patient with BRCA2 Mutation and HER2-Overexpressing Breast Cancer Involving the Brain
by: Anna Koumarianou, et al.
Published: (2016-01-01)

Expanding applications of MRI-based radiomics in HER2-positive breast cancer
by: Vivian Y. Park
Published: (2020-11-01)

Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations
by: Lamond NW, et al.
Published: (2014-05-01)

Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer
by: Koji Takada, et al.
Published: (2018-04-01)

Precision medicine and personalized breast cancer: combination pertuzumab therapy
by: Reynolds K, et al.
Published: (2014-03-01)

Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
by: Oostra DR, et al.
Published: (2014-07-01)

Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab
by: Gollamudi J, et al.
Published: (2016-02-01)

Treatment of HER2 positive breast cancer patients
by: Erika Matos
Published: (2012-03-01)

Target therapy in treatment of HER2-positive breast cancer
by: A. S. Belokhvostova, et al.
Published: (2016-02-01)

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
by: Edith A. Perez, et al.
Published: (2019-05-01)

Phase II neoadjuvant trial of Albumin-Bound Paclitaxel, Trastuzumab and Pertuzumab followed by anthracycline based regimens in patients with operable Her2 positive breast cancer (OMC-BC05)
by: M. Iwamoto, et al.
Published: (2021-04-01)

Efficacy of trastuzumab-emtansine in breast cancer patients prior treated with pertuzumab
by: Sundfors, Anu-Johanna
Published: (2019)

Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer
by: Hurvitz SA, et al.
Published: (2012-04-01)